1 |
CPT1C
| [8] Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Adipocytokine signaling pathway, Glucagon signaling pathway, Alcoholic liver disease | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
2 |
CPT1A
| [9] Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
3 |
CPT1B
| [10] Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease, Diabetic cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
4 |
CPT2
| [5] Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, Thermogenesis, Diabetic cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
5 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
6 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
7 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
8 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
9 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
10 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
11 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
12 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
13 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
14 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
15 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
16 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
17 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
18 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
19 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
20 |
ABL1
| [11] ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D09664
D09664
|
Saracatinib
| [3] 6 6, 89, 272 |
21 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
22 |
RARG
| - | D09365
D09365
|
Palovarotene
| [1] 272 272 |
23 |
SRC
| [42] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, Axon guidance, VEGF signaling pathway, Focal adhesion, Adherens junction, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Bacterial invasion of epithelial cells, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Bladder cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09664
D09664
|
Saracatinib
| [3] 6 6, 89, 272 |
24 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
25 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
26 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |
27 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| [2] 58 58, 272 |